Difference between revisions of "Talquetamab (Talvey)"
Jump to navigation
Jump to search
m |
m (Jwarner moved page Talquetamab (JNJ-64407564) to Talquetamab (Talvey): FDA approval) |
Revision as of 14:42, 10 August 2023
Mechanism of action
From the NCI Drug Dictionary: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells.
Diseases for which it is established
- MonumenTAL-1: Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. Epub 2022 Dec 10. link to original article PubMed NCT03399799
History of changes in FDA indication
- 2023-08-09: Granted accelerated approval for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Based on MonumenTAL-1)
Also known as
- Code name: JNJ-64407564
- Generic name: talquetamab-tgvs
- Brand name: Talvey